 |
|
|
| |
Long-term HBsAg suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects
|
| |
| |
EASL 2022 June 22-26 London
Man-Fung Yuen1, Elina Berliba2, Wattana Sukeepaisarnjaroen3, Jacinta Holmes4, Apinya Leerapun5, Pisit Tangkijvanich6, Simone I Strasser7, Alina Jucov2, Edward Gane8, Emily P Thi9, Heather Sevinsky10, Elina
Medvedeva10, Varun Sharma10, Kevin Gray10, Deana Antoniello10, Gaston Picchio10, Karen D Sims10, Timothy Eley10.
1Queen Mary Hospital, The University of Hong Kong, Hong Kong, 2Arensia Exploratory Medicine, Moldova, 3Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand, 4St. Vincent's Hospital, Melbourne, Australia, 5Chiang Mai University Chiang Mai, Thailand, 6Chulalongkorn University, Bangkok, Thailand, 7Royal Prince Alfred Hospital, Sydney, Australia, 8Auckland Clinical Studies, New Zealand, 9Arbutus Biopharma Discovery and Research, 10Arbutus Biopharma Clinical Development
• Robust declines in HBsAg were observed in most subjects and maintained well after the cessation of AB-729 treatment; mean log change from baseline 24 weeks post last dose is approximately -1.5 log10 across cohorts
• Twenty-six of 34 subjects in these 5 cohorts had HBsAg < 100 IU/mL at some point during the study
• Eleven subjects in these cohorts were HBeAg-, HBV DNA < LLOQ, and HBsAg <100 IU/mL with ALT< 2xULN at least 24 weeks post last dose of AB-729 and qualified to discontinue NA therapy; 9 subjects have consented
• NA discontinuation subjects are identified in the figures above by a masked subject ID consistent with the AB-729-001 NA discontinuation poster SAT448
• One subject in Cohort E (baseline HBsAg = 583.5 IU/mL) who qualified but declined to participate in NA discontinuation seroconverted at Week 84 (HBsAg < LLOQ and HBsAb = 189 mIU/mL at last visit); liver enzymes remained within normal limits.
|
| |
|
|
|
|
|
